Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. Issue 10 (1st May 2022)
- Record Type:
- Journal Article
- Title:
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers. Issue 10 (1st May 2022)
- Main Title:
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers
- Authors:
- Liang, Beibei
Wang, Jin
Bai, Nan
Chi, Yulong
Wang, Rui
Cai, Yun - Abstract:
- Abstract: Youkenafil hydrochloride is a novel selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. Its safety, tolerability, and pharmacokinetics were evaluated in healthy Chinese male volunteers. In addition, this study explored the effect of food on the pharmacokinetic parameters of youkenafil hydrochloride. The study was divided into 3 trials: a single ascending dose (25, 50, 100, 150, or 200 mg youkenafil), multiple dose (50, 100, or 150 mg youkenafil once daily for 7 consecutive days), and food effect (50 mg youkenafil single dose). The overall tolerability of youkenafil was good. Youkenafil was rapidly absorbed after a single oral dose. Food intake impeded absorption efficiency but had no significant effect on area under the plasma concentration–time curve values. The mean accumulation ratio in area under the plasma concentration–time curve and maximum plasma concentration ranged from 1.3 to 1.6 and from 1.2 to 1.4 after once‐daily dosing. There was no apparent accumulation following consecutive administration for 7 days. Less than 1% of the dose was found in urine as the intact drug for all dose groups. Single‐dose youkenafil up to 200 mg and multiple doses up to 150 mg were generally safe and well tolerated.
- Is Part Of:
- Clinical pharmacology in drug development. Volume 11:Issue 10(2022)
- Journal:
- Clinical pharmacology in drug development
- Issue:
- Volume 11:Issue 10(2022)
- Issue Display:
- Volume 11, Issue 10 (2022)
- Year:
- 2022
- Volume:
- 11
- Issue:
- 10
- Issue Sort Value:
- 2022-0011-0010-0000
- Page Start:
- 1184
- Page End:
- 1190
- Publication Date:
- 2022-05-01
- Subjects:
- food effects -- pharmacokinetics -- phosphodiesterase type 5 inhibitor -- safety -- youkenafil hydrochloride
Drugs -- Testing -- Periodicals
Drug development -- Periodicals
Clinical pharmacology -- Periodicals
615.580724 - Journal URLs:
- http://cpd.sagepub.com ↗
http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292160-7648 ↗
http://accp1.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2160-7648/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cpdd.1108 ↗
- Languages:
- English
- ISSNs:
- 2160-7648
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330300
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23997.xml